GE Launches new Voluson E10 featuring world's first curved electronic 4D probe and next generation of HDlive
Barcelona, Spain September 15, 2014 - GE Healthcare announced today commercial availability in the U.S, Europe and Japan for its new Voluson E10 ultrasound system featuring the world's first curved matrix electronic 4D probe designed specifically for OB/GYN and the next generation version of its HDlive software.
Wauwatosa, WI, September 3, 2014 --- GE Healthcare (NYSE: GE) today announced the FDA approval of SenoClaire*, GE's new breast tomosynthesis solution designed with a three-dimensional imaging technology. In collaboration with Massachusetts General Hospital, GE developed SenoClaire technology that uses a low-dose short X-ray sweep around the positioned breast with nine exposures acquired with a "step-and-shoot" method, removing the potential motion from the tube helping to reduce blur and increase image sharpness.
FAIRFIELD, Conn. --- Today the GE Foundation announced a USD$20MM commitment to advance maternal and child health in Africa, through the extension of programs that address Millennium Development Goals (MDGs) 4 and 5. The commitment supports developing countries in implementing simple and sustainable solutions for maternal health and child survival rates, and strengthening regional health systems.
SUNNYVALE, Calif., October 24, 2013 -- GE Healthcare today announced that the somo*vTMINSIGHT System was recognized as the category leader with the highest ranking in Women's Imaging (Specialty) in the 2013 Best in KLAS Awards: Medical Equipment & Infrastructure Report. The Best in KLAS Awards Report ranked imaging, pharmacy automation and infrastructure vendors. This year, over 180 products were ranked by healthcare providers.
Implementation of the somo*vTM ABUSTM as an adjunctive screening modality in Routine Clinical Practice is Feasible
SUNNYVALE, Calif., Thursday, September 19, 2013 -- The addition of Automated Breast Ultrasound (ABUS) demonstrated increased interreader agreement when used in combination with mammography compared to mammography alone for women with dense breasts, according to a study published in a recent issue of Academic Radiology (July 2103, Volume 20, Issue 7, 847-853).
WAUKESHA, WI -- July 30, 2013-- GE Healthcare, a unit of General Electric Company (NYSE:GE), announced that it recently submitted to the U.S. Food and Drug Administration (FDA) the final module of its premarket approval application (PMA[1]) for GE Breast Tomosynthesis, an option of the Senographe* Essential system.
